EU Grants VIDAZA® Full Marketing Authorization For The Treatment Of Patients With Higher-Risk Myelodysplastic Syndromes And Acute Myeloid Leukaemi
Celgene International SÃ rl (Nasdaq:CELG) today announced that its cancer drug, VIDAZA (azacitidine), has been granted full marketing authorization by the European Commission for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: — I
More: continued here
Filed under: Blood on January 3rd, 2009